TERNS PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.915 USD | -0.25% |
|
-3.75% | -8.94% |
| 05-13 | Terns Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 05-08 | Terns Pharmaceuticals, Inc. Announces Executive Changes | CI |
Presenter SpeechMayank Mamtani (Analysts)Good afternoon for folks on the East Coast, and good ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
Calendar
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
5.93
USD
Average target price
14.21
USD
Spread / Average Target
+139.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.94% | 384M | |
| +63.85% | 62.59B | |
| -1.78% | 41.18B | |
| +44.76% | 40.29B | |
| -8.93% | 27.9B | |
| +12.58% | 26.21B | |
| -21.84% | 19.09B | |
| +4.26% | 13.08B | |
| +25.62% | 12.26B | |
| +28.18% | 12.05B |
- Stock Market
- Equities
- TERN Stock
- News Terns Pharmaceuticals, Inc.
- Transcript : Terns Pharmaceuticals, Inc. Presents at B. Riley Securities' 3rd Annual Oncology Conference, Jan-18-2023 02
